Survey results demonstrate patient satisfaction with Somatuline® Autogel®/Somatuline® Depot (lanreotide)
Data from two patient surveys, PRESTO2 and HomeLAN, has demonstrated patient-reported benefits for those administering Somatuline® Autogel®/Somatuline® Depot (lanreotide). The findings were presented at the 19th Annual ENETS Conference, 10−11 March 2022 (Barcelona, Spain). PRESTO2 was an e-survey, investigating injection site pain in those living with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) or acromegaly (n=219 and n=85). The HomeLAN survey, evaluated the injection experience satisfaction of people living with GEP-NETs who participate in patient support programs (PSPs). The results include fewer patients who reported injection-site pain, high levels of satisfaction for those enrolled on patient support programs and patients feeling satisfied with...